Clinical Trial

Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy

CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of…

3 weeks ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed…

3 weeks ago

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical…

3 weeks ago

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size…

3 weeks ago

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing…

3 weeks ago

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the…

3 weeks ago

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated…

3 weeks ago

BioLizard Launches Bio|Verse® Navigator for Easy Exploration of Complex Biomedical Data

Bio|Verse Navigator can accelerate data exploration and interpretation workflows multifold, reducing time-to-insight for researchers.The application combines advanced BioLizard’s bioinformatics expertise…

3 weeks ago

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination…

3 weeks ago

New Study Indicates SpotitEarly Detects Multiple Cancers Early By Using AI, Trained Canines And Breath Samples

Innovative platform can identify breast, lung, prostate and colorectal cancers with a single, non-invasive test ENGLEWOOD, N.J., Dec. 4, 2024…

3 weeks ago